Lung Cancer Screening Market Report 2026

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.33 billion in 2025 to $3.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising incidence of lung cancer among aging populations, increased awareness of early screening benefits, expansion of diagnostic imaging infrastructure, improvements in ct imaging technology, adoption of guideline-based screening protocols.

The lung cancer screening market size is expected to see strong growth in the next few years. It will grow to $5.24 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing adoption of ai-assisted diagnostic workflows, expansion of population-based screening programs, growing focus on personalized risk assessment, rising investments in early cancer detection technologies, increasing healthcare policy support for screening. Major trends in the forecast period include increasing adoption of low-dose ct screening programs, rising integration of ai in imaging analysis, growing focus on high-risk population screening, expansion of preventive oncology initiatives, enhanced emphasis on early lung cancer detection.

The increasing smoking rates are expected to drive the growth of the lung cancer screening market going forward. Smoking refers to the act of inhaling smoke produced by burning substances, most commonly tobacco, through the mouth and into the lungs. The rise in smoking rates is attributed to growing stress levels, which have led more individuals to adopt smoking as a coping mechanism. Lung cancer screening plays a role in addressing rising smoking rates by supporting the early identification of smoking-related health risks, which can encourage smoking cessation and contribute to broader public health initiatives aimed at reducing tobacco use. For instance, in October 2024, according to the Office for Health Improvement & Disparities, a UK-based government organization, the prevalence of current smokers within the routine and manual occupation group aged 18 to 64 was 19.5% in 2023. Therefore, the increasing smoking rates are contributing to the expansion of the lung cancer screening market.

Key companies operating in the lung cancer screening market are concentrating on the development of advanced solutions, such as normal flagging, to improve diagnostic accuracy, minimize false positives, and strengthen early detection of cancerous nodules. Normal flagging is a technological capability in lung cancer screening that automatically identifies and marks scans with no abnormal findings, allowing healthcare professionals to prioritize cases requiring further evaluation. For example, in May 2025, Lunit Inc., a South Korea-based medical technology company, launched INSIGHT CXR4, its next-generation artificial intelligence (AI)-powered chest X-ray analysis solution, which received CE MDR certification for use across Europe. The solution is designed to support radiologists by enhancing diagnostic accuracy and workflow efficiency, detecting 12 chest abnormalities such as lung nodules, pneumonia, and acute bone fractures, and incorporating features like current-to-prior image comparison to aid early disease detection and clinical decision-making.

In May 2025, Johnson & Johnson MedTech, a US-based healthcare technology company, entered into a partnership with Qure.ai to advance early lung cancer detection in India. Through this collaboration, Johnson & Johnson MedTech sought to strengthen its AI-driven diagnostic capabilities and broaden access to early-stage lung cancer screening by establishing AI-enabled Incidental Pulmonary Nodule (IPN) detection clinics across major hospitals in India. QURE AI TECHNOLOGIES PRIVATE LIMITED is an India-based healthcare technology company specializing in AI-powered medical imaging solutions, including X-ray and CT-based automated lung nodule detection, triage, and IPN management.

Major companies operating in the lung cancer screening market are Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, Toshiba Medical Systems Corporation.

North America was the largest region in the lung cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the lung cancer screening market by increasing costs of imported CT scanners, imaging software, diagnostic accessories, and maintenance components. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported imaging equipment, while Asia-Pacific faces higher costs for scanner manufacturing and deployment. These tariffs are increasing capital investment requirements and slowing equipment upgrades. However, they are also encouraging local assembly of imaging systems, regional technology partnerships, and domestic development of diagnostic imaging solutions.

The lung cancer screening market research report is one of a series of new reports that provides lung cancer screening market statistics, including lung cancer screening industry global market size, regional shares, competitors with a lung cancer screening market share, detailed lung cancer screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer screening industry. This lung cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung cancer screening is a preventive approach focused on detecting cancer in the lungs at an early stage, often before visible symptoms appear. It targets individuals who may be at elevated risk due to certain health conditions or lifestyle-related factors. The objective of this process is to identify abnormal changes or growths in lung tissue at an early stage, which can enhance the likelihood of effective treatment and lessen the overall burden of the disease.

The primary diagnostic types of lung cancer screening include low-dose spiral computed tomography scans and chest X-rays. A low-dose spiral computed tomography scan is an imaging method that employs low levels of radiation to generate detailed cross-sectional images of the lungs, allowing for early identification of lung abnormalities with high sensitivity. This technique is used to screen for various cancer types, such as non-small cell lung cancer and small cell lung cancer, across different age groups, including individuals aged 50 and older as well as those below 50. It is utilized by multiple end users, including hospitals and clinics, diagnostic centers, and others.

The lung cancer screening market includes revenues earned by entities by providing services such as radiology interpretation, diagnostic follow-up procedures, patient risk assessment, and telehealth consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.